Last year, as the public made Pfizer, Johnson & Johnson, and Moderna household names, pharmaceutical companies took their cue. They poured more cash into unbranded campaigns compared to past years. Also under discussion this week is an intriguing executive move at Novartis. CEO Vas Narasimhan created a new position to oversee the company’s corporate strategy—then hired a high-profile Wall Street analyst to take the lead. And a journalist from Fierce Life Sciences heads to the Azbee Awards.
To learn more about the topics in this episode:
- The top advertisers in Big Pharma
- Novartis hires seasoned Wall Street analyst Ronny Gal as new M&A czar
- Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger
- Pfizer's blood pressure med recall creeps into US as testing flags carcinogen threat
- Ardelyx's Hail Mary caught, as FDA agrees on appeal to convene advisory committee for tenapanor
- Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna
- Nektar guts workforce, weeks after $3.6B Bristol Myers immuno-oncology collaboration ends
- Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe
- SURMOUNT-able: Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity
The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.
Follow The Top Line on iTunes, Spotify, Amazon, iHeart Radio or wherever you get your podcasts.